Omnimed now provides you with instant access to evidence-based deprescribing tools for sedative-hypnotics (benzodiazepines and Z-drugs), proton pump inhibitors (PPIs) and opioids for chronic non-cancer pain.
The following tools are now accessible:
- A personalised audit report, identifying your patients aged ≥65 years who have been prescribed a sedative-hypnotic, PPI or opioid for longer than 12 weeks
- Clinical tools allowing you to identify if the deprescribing process should be started for your patient.
- Whiteboard videos with tips including starting a deprescribing conversation with patients and how to minimise rebound symptoms
- Deprescribing algorithms
- Online opioid tapering calculator
- Patient educational brochures that can either be printed or emailed directly to your patient
To ensure the deprescribing tools are useful and of interest, Omnimed and the Université de Montréal are collecting anonymous data relating to their use.
You will be provided with information about your patients within your personalized report, however, only anonymous aggregate usage data will be collected and analyzed. No information about the prescription or deprescription of any medication will be collected.
By clicking on the link below and accessing the tools, you consent for anonymous usage data to be collected and analyzed for reporting purposes. If you have any questions or would like additional information, please email firstname.lastname@example.org.
You have to read the Information and consent form
How it works
- First, access the report allowing you to identify the patients who might be subject to a deprescribing process
- Click on the name of the patient in the report to access his medical record.
- Use the deprescribing clinical tools, available within the Deprescribing group.
- Click on the link at the bottom of the clinical tool to learn more about the clinical practice guidelines.
- If needed, consult the resources available (educational video, deprescribing algorithm, patient brochure)
- Visit the report frequently to see if new patients are subject to the deprescribing process.